Hu X J, Ticku M K
Department of Pharmacology, University of Texas Health Science Center, San Antonio 78284-7764.
Mol Pharmacol. 1994 Apr;45(4):618-25.
We have investigated the effect of chronic flurazepam HCl treatment on the gamma-aminobutyric acid (GABA)A receptor complex in cultured mammalian cortical neurons. Chronic flurazepam (1-5 microM, for 1-10 days) treatment did not produce any changes in the morphological appearance or the cell protein content of cortical neurons. The basal binding of [3H]flunitrazepam, [3H] Ro15-1788, and [3H]Ro15-4513 was also not altered after the chronic treatment. However, chronic flurazepam treatment produced uncoupling between GABA and pentobarbital sites and the [3H]flunitrazepam binding site. The EC50 values of GABA and pentobarbital were not significantly altered after chronic flurazepam treatment; however, their Emax values were decreased by approximately 50%. The effect of chronic flurazepam treatment on the observed uncoupling was both time and concentration dependent. Furthermore, the binding of [3H]GABA and t-butylbicyclophosphoro[35S]thionate was also not altered by chronic flurazepam treatment. The effect of GABA on 36Cl influx was not altered after chronic flurazepam treatment; however, treatment significantly attenuated the ability of diazepam to enhance GABA-induced 36Cl influx. Chronic flurazepam-induced uncoupling and decreased diazepam efficacy were reversed by the concomitant presence of the benzodiazepine antagonist Ro15-1788, suggesting that these events are mediated via the benzodiazepine receptor site. Taken together, these results suggest that chronic benzodiazepine treatment produces uncoupling of GABA and pentobarbital sites from the benzodiazepine site and decreased coupling between the benzodiazepine site and GABA receptor-gated Cl- channels. The uncoupling and decreased efficacy may be due to an alteration in the levels of various alpha subunits and may be responsible for the tolerance associated with chronic benzodiazepine agonist treatment.
我们研究了长期盐酸氟西泮治疗对培养的哺乳动物皮质神经元中γ-氨基丁酸(GABA)A受体复合物的影响。长期使用氟西泮(1-5微摩尔,持续1-10天)治疗并未使皮质神经元的形态外观或细胞蛋白含量发生任何变化。长期治疗后,[3H]氟硝西泮、[3H]Ro15-1788和[3H]Ro15-4513的基础结合也未改变。然而,长期使用氟西泮治疗导致GABA和戊巴比妥位点与[3H]氟硝西泮结合位点之间发生解偶联。长期使用氟西泮治疗后,GABA和戊巴比妥的EC50值没有显著改变;然而,它们的Emax值下降了约50%。长期使用氟西泮治疗对观察到的解偶联的影响具有时间和浓度依赖性。此外,长期使用氟西泮治疗也未改变[3H]GABA和叔丁基双环磷硫代酸酯的结合。长期使用氟西泮治疗后,GABA对36Cl内流的影响未改变;然而,该治疗显著减弱了地西泮增强GABA诱导的36Cl内流的能力。苯二氮䓬拮抗剂Ro15-1788的同时存在可逆转长期氟西泮诱导的解偶联和地西泮疗效降低,这表明这些事件是通过苯二氮䓬受体位点介导的。综上所述,这些结果表明,长期使用苯二氮䓬治疗会导致GABA和戊巴比妥位点与苯二氮䓬位点解偶联,并降低苯二氮䓬位点与GABA受体门控Cl-通道之间的偶联。这种解偶联和疗效降低可能是由于各种α亚基水平的改变,并且可能是与长期苯二氮䓬激动剂治疗相关的耐受性的原因。